Nathaniel Hearn Jr.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.

Cooley advised Yieldstreet, a leading private market investing platform, on its acquisition of Cadre, an online real estate-focused investment platform that serves institutional and high net worth investors.

Cooley advised MadCap Software, a multichannel content authoring, management and publishing solutions provider, on its acquisition of Xyleme, which offers intelligent content management for the development, control, delivery, and syndication of vital proprietary learning and development content across the enterprise.